Merck (NYSE: MRK) announced that Japan's Ministry of Health, Labor and Welfare has approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE